Kintegral Advisory LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 32.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 83,631 shares of the biopharmaceutical company's stock after selling 41,015 shares during the quarter. Gilead Sciences makes up about 1.4% of Kintegral Advisory LLC's investment portfolio, making the stock its 8th largest holding. Kintegral Advisory LLC's holdings in Gilead Sciences were worth $9,371,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC lifted its holdings in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth about $339,000. Fisher Asset Management LLC lifted its position in shares of Gilead Sciences by 18.5% in the fourth quarter. Fisher Asset Management LLC now owns 10,606 shares of the biopharmaceutical company's stock worth $980,000 after buying an additional 1,656 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its position in shares of Gilead Sciences by 12.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 45,818 shares of the biopharmaceutical company's stock valued at $4,232,000 after acquiring an additional 5,116 shares during the last quarter. Finally, Bahl & Gaynor Inc. purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $217,000. Hedge funds and other institutional investors own 83.67% of the company's stock.
Insider Activity at Gilead Sciences
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the transaction, the chief financial officer directly owned 165,110 shares in the company, valued at approximately $18,190,168.70. The trade was a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the completion of the transaction, the chief executive officer owned 615,725 shares in the company, valued at $68,006,826.25. This trade represents a 1.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 58,500 shares of company stock worth $6,340,745 in the last 90 days. 0.27% of the stock is owned by insiders.
Gilead Sciences Stock Down 0.2%
Gilead Sciences stock traded down $0.24 during trading on Friday, reaching $111.28. The stock had a trading volume of 4,039,811 shares, compared to its average volume of 7,692,289. Gilead Sciences, Inc. has a 52-week low of $66.01 and a 52-week high of $119.96. The business has a 50 day moving average price of $106.85 and a 200 day moving average price of $103.80. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The stock has a market cap of $138.42 billion, a PE ratio of 23.43, a P/E/G ratio of 0.72 and a beta of 0.29.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the prior year, the company posted ($1.32) earnings per share. Gilead Sciences's revenue for the quarter was down .3% compared to the same quarter last year. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.
Analyst Upgrades and Downgrades
A number of research firms recently commented on GILD. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target for the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Morgan Stanley increased their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Finally, Oppenheimer lowered their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $110.55.
Get Our Latest Stock Report on Gilead Sciences
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
